Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), by Indication (Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Kidney Cancer) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — announces the release of the report “Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025 – Cumulative Impact of COVID-19” –

The Global Cancer Diagnostics Market is expected to grow from USD 140,325.96 Million in 2019 to USD 221,237.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.88%.

Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and

Read More

Aesthetic Medicine and Cosmetics Market 2020 Global Analysis, Opportunities And Forecast to 2025

“Aesthetic Medicine and Cosmetics Market”

Wiseguyreports.Com Adds “Aesthetic Medicine and Cosmetics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

Aesthetic Medicine and Cosmetics Industry


Wiseguyreports.Com Adds “Aesthetic Medicine and Cosmetics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Aesthetic Medicine and Cosmetics by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

This report contains opportunities, strengths, threats, and weaknesses (SWOT) analysis for this market. They have taken many aspects into account for analysis, including sales volume, revenue level of the last few years, product demands, customer retention, etc. A majority of information has been collected from primary sources, and analysts have taken effective samples. As the market size is large, analysts have taken large sample sizes from different regions of the globe. They also calculated the Aesthetic Medicine and Cosmetics Market’s customer churns level because it plays a vital role in sales volume. This research analysis report can help this Aesthetic Medicine and Cosmetics Market to become sustainable in the market from a global context.

Request For Sample Report @

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

NuYu Medispa
Al Qamra Holding Group
Premium Naseem
Dr. Makki Plastic Surgicentre
Medica Group
Al Emadi Hospital

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Surgical Procedures
Non-Surgical Procedures

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
Hospitals & Clinics
Beauty Centers & Medical Spas

Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)

Leave a Query @


Table of Contents

1 Industry Overview
1.1 Aesthetic Medicine and Cosmetics Industry
Figure Aesthetic Medicine and Cosmetics Industry Chain Structure
1.1.1 Overview
1.1.2 Development of Aesthetic Medicine and Cosmetics
1.2 Market Segment
1.2.1 Upstream
Table Upstream Segment of Aesthetic Medicine and Cosmetics
1.2.2 Downstream
Table Application Segment of Aesthetic Medicine and Cosmetics
Table Global Aesthetic Medicine and Cosmetics Market 2015-2025, by Application, in USD Million
1.3 Cost Analysis

2 Industry Environment (PEST Analysis)
2.1 Policy
2.2 Economics
2.3 Sociology
2.4 Technology


4 Major Companies List
4.1 NuYu Medispa (Company Profile, Sales Data etc.)
4.1.1 NuYu Medispa Profile
Table NuYu Medispa Overview List
4.1.2 NuYu Medispa Products & Services
4.1.3 NuYu Medispa Business Operation Conditions
Table Business Operation of NuYu Medispa (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.2 Al Qamra Holding Group (Company Profile, Sales Data etc.)
4.2.1 Al Qamra Holding Group Profile
Table Al

Read More

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

Amgen and Eisai to Participate in the Immune Modulation Domain of REMAP-COVID, an Adaptive Clinical Trial to Test Interventions for Patients Hospitalized With COVID-19

Amgen’s Apremilast and Eisai’s Eritoran to Be Evaluated Across Multiple International Trial Sites Within the REMAP Network

Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai Co., Ltd., today announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. Amgen’s apremilast and Eisai’s investigational eritoran are being evaluated as potential therapeutic agents.

This press release features multimedia. View the full release here:

REMAP-CAP was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID sub-study), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized platform study, with treatments tested within groupings or “domains” based on pathway or mechanism of action.

The trial is being conducted in the multi-hospital UPMC (University of Pittsburgh Medical Center) health system along with over 20 hospitals in the United States. Additional global sites across the trial network will follow. University of Pittsburgh is serving as the U.S. Regional Coordinating Center.

“Partnering with the biopharmaceutical industry to be able to efficiently test well-understood targeted agents is critical to understanding treatment paradigms for COVID-19 patients,” says Derek Angus, MD, MPH, FRCP, U.S. Principal Investigator of REMAP and Chief Healthcare Innovation Officer, UPMC Health System. “Today’s announcement marks an important milestone in the collaboration between industry and the scientific and academic community to work collectively to evaluate potentially promising therapies to support patients hospitalized with COVID-19.”

Amgen’s apremilast is an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4, apremilast is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients. Apremilast is currently approved for use in more than 45 countries as an oral treatment for inflammatory diseases including moderate to severe plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease.

“Amgen believes that, based on its mechanism of action, apremilast might help prevent the respiratory distress seen in moderate to severe-stage adult COVID-19 patients,” said David M. Reese, M.D., Executive Vice President of Research and Development at Amgen. “We are proud to be joining REMAP-COVID, which is an important and innovative effort utilizing a platform approach and has the potential to rapidly identify whether apremilast

Read More

Global Blood Ketone Meter Market to Surpass US$ 486.3 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global blood ketone meter market is estimated to be valued at US$ 301.7 million in 2020 and is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027).

Key Trends and Analysis of the market:

The increasing number of product launches is expected to drive growth of the blood ketone meter market during the forecast period. For instance, in March 2020, EKF Diagnostics, the global in vitro diagnostics company, announced the launch of the U.S. FDA CLIA-waived β-ketone and glucose POC analyzer STAT-Site WB Analyzer in the U.S. market. This device is a new addition to its diabetes care portfolio in the U.S. The STAT-Site WB is a dual-use whole blood β-ketone and glucose meter for professional use in the management of diabetes.

Key manufacturers operating in the blood ketone meter market are engaged in developing more advanced products for the ease of diabetes patients. For instance, blood glucose & ketone testing meter by Foracare Inc., called FORA 6 Gtel, is a device that comes with 3G/4G connectivity. It can seamlessly transfer data to a TeleHealth System without the need for pairing it with a smartphone. With 5-Electrode Technology and strips made with gold, FORA 6 test strips ensure high accuracy and precision. It measures six parameters such as glucose, hematocrit, hemoglobin, β-ketone, total cholesterol, and uric acid in blood.

The global blood ketone meter market is expected to witness significant growth, owing to increasing partnerships and collaborations. For instance, in February 2020, the global diabetes nonprofit Beyond Type 1 announced a new collaboration with the National Association of School Nurses to create awareness about the warning signs of type 1 diabetes (T1D). With this new collaboration, awareness materials will be distributed to tens of thousands of school nurses nationally in the U.S. Moreover, Beyond Type 1 advocates will be enhancing efforts in ten target states: Arkansas, Connecticut, Florida, Massachusetts, New Jersey, North Carolina, Ohio, Oklahoma, Pennsylvania, and Texas.

Request Sample Copy of this Report @

Key Market Takeaways:

The global blood ketone meter market is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027), owing to the rising prevalence of type 1 diabetes worldwide. For instance, according to the National Diabetes Statistics Report by Centers for Disease Control and Prevention of 2017, around 1.25 million Americans suffered from type 1 diabetes and over 300,000 Canadians lived with type 1 diabetes in 2017. Furthermore, as per the same source, over 100,000 children in India and 50,000 children and adolescents in China were living with type 1 diabetes as of 2017.

Key players in the North America blood ketone meter market are focused on launching new products, which is expected to drive growth of the market during the forecast period. For instance, in March 2020, EKF Diagnostics launched the STAT-Site WB, a blood β-ketone and glucose meter in the U.S. The device is used for measuring ketone and for the management of diabetes.

Competitive Landscape:

Key players

Read More

Global Animal Healthcare Market – Featuring Bayer AG, C. H. Boehringer Sohn AG & Co. KG, and Cadila Healthcare Ltd. Among Others

The animal healthcare market is poised to grow by USD 7.98 billion during 2020-2024, progressing at a CAGR of over 4% during the forecast period.

This press release features multimedia. View the full release here:

Technavio has announced its latest market research report titled Global Animal Healthcare Market 2020-2024 (Graphic: Business Wire)

The report on the animal healthcare market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rise in incidences of zoonotic diseases.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The animal healthcare market analysis includes the product segment and geographic landscapes. This study identifies the increasing role of organic tracing elements in improving livestock production as one of the prime reasons driving the animal healthcare market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The Animal Healthcare Market covers the following areas:

Animal Healthcare Market Sizing

Animal Healthcare Market Forecast

Animal Healthcare Market Analysis

Companies Mentioned

  • Bayer AG

  • C. H. Boehringer Sohn AG & Co. KG

  • Cadila Healthcare Ltd.

  • Dechra Pharmaceuticals Plc

  • Elanco Animal Health Inc.

  • Heska Corp.

  • Merck & Co. Inc.

  • Norbrook Laboratories Ltd.

  • Virbac SA

  • Zoetis Inc.

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem

  • Value chain analysis

Market Sizing

Five Forces Analysis

Market Segmentation by Product

  • Market segments

  • Comparison by Product placement

  • Pharmaceutical – Market size and forecast 2019-2024

  • Feed additive – Market size and forecast 2019-2024

  • Biologicals – Market size and forecast 2019-2024

  • Market opportunity by Product

Customer landscape

Geographic Landscape

  • Geographic segmentation

  • Geographic comparison

  • North America – Market size and forecast 2019-2024

  • Europe – Market size and forecast 2019-2024

  • APAC – Market size and forecast 2019-2024

  • South America – Market size and forecast 2019-2024

  • MEA – Market size and forecast 2019-2024

  • Key leading countries

  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers

  • Volume driver – Demand led growth

  • Volume driver – Supply led growth

  • Volume driver – External factors

  • Volume driver – Demand shift in adjacent markets

  • Price driver – Inflation

  • Price driver – Shift from lower to higher-priced units

  • Market challenges

  • Market trends

Vendor Landscape

  • Overview

  • Vendor landscape

  • Landscape disruption

Vendor Analysis

  • Vendors covered

  • Market positioning of vendors

  • Bayer AG

  • C. H. Boehringer Sohn AG & Co. KG

  • Cadila Healthcare Ltd.

  • Dechra Pharmaceuticals Plc

  • Elanco Animal Health Inc.

  • Heska Corp.

  • Merck & Co. Inc.

  • Norbrook Laboratories Ltd.

  • Virbac SA

  • Zoetis Inc.


About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize

Read More

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions.    


Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.

Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.

The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.

In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function are few,

Read More

A Snapshot of COVID’s Global Havoc

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Some medical societies feature sessions at their annual meetings that feel like they’re 24 hours long, yet few have the courage to schedule a session that actually runs all day and all night. But the five societies sponsoring the IDWeek conference had that courage. The first 24 hours of the meeting was devoted to the most pressing infectious-disease crisis of the last 100 years: the COVID-19 pandemic. They called it “COVID-19: Chasing the Sun.”

Fauci Predicts a Vaccine Answer in Mid-November

Dr Anthony Fauci

In the first segment, at 10 am Eastern time, Anthony Fauci, MD, director of the US National Institute of Allergy and Infectious Diseases and the nation’s top infectious-disease expert, began the day by noting that five of the six companies the US invested in to develop a vaccine are conducting phase 3 trials. He said, “We feel confident that we will have an answer likely in mid-November to the beginning of December as to whether we have a safe and effective vaccine”. He added he was “cautiously optimistic” that “we will have a safe and effective vaccine by the end of the year, which we can begin to distribute as we go into 2021.” He highlighted the COVID-19 Prevention Network website for more information on the trials.

Glaring Racial Health Disparities in US

Dr Carlos del Rio

Some of the most glaring health disparities surrounding COVID-19 in the United States were described by Carlos del Rio, MD, professor of medicine at Emory University in Atlanta, Georgia. He pointed out that while white people have about 23 cases per 10,000 population, Blacks have about 62 cases per 10,000, and Latinos have 73 cases per 10,000. While whites don’t see a huge jump in cases until age 80, he said, “Among Blacks and Latinos you start seeing that huge increase at a younger age. In fact, starting at age 20, you start seeing a major, major change.”

COVID-19 Diagnostics

Audrey Odom John, MD, PhD, chief of pediatric infectious diseases at Children’s Hospital of Philadelphia, is working on a new way of diagnosing COVID-19 infection in children by testing their breath. “We’re really taking advantage of a fundamental biological fact, which is that people stink,” she said. Breath shows the health of the body as a whole, “and it’s easy to see how breath volatiles might arise from a respiratory infection.” Testing breath is easy and inexpensive, which makes it particularly attractive as a potential test globally, she said.

Long-term Effects of COVID-19

Post-COVID illness threatens to overwhelm the health system in the United States, even if only 1% of the 8 million people who have been infected have some sort of long-term deficit, “which would be a very conservative estimate,” said John O’Horo, MD, MPH, with the Mayo Clinic in Rochester, Minnesota. Neurologic dysfunction is going to be a “fairly significant thing to keep an eye on,” he added. Preeti Malani, MD, chief health

Read More

Global Wireless Health and Fitness Devices Market 2020-2027

DUBLIN, Oct. 23, 2020 /PRNewswire/ — The “Wireless Health and Fitness Devices – Global Market Trajectory & Analytics” report has been added to’s offering.

Global Wireless Health and Fitness Devices Market to Reach 464.6 Million Units by 2027

Amid the COVID-19 crisis, the global market for Wireless Health and Fitness Devices estimated at 221.6 Million Units in the year 2020, is projected to reach a revised size of 464.6 Million Units by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027.

Sports & Fitness, one of the segments analyzed in the report, is projected to record a 10.1% CAGR and reach 280.4 Million Units by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Remote Health Monitoring segment is readjusted to a revised 12.1% CAGR for the next 7-year period.

The U. S. Market is Estimated at 59.9 Million Units, While China is Forecast to Grow at 14.7% CAGR

The Wireless Health and Fitness Devices market in the U. S. is estimated at 59.9 Million Units in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of 99.2 Million Units by the year 2027 trailing a CAGR of 14.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.8% and 9.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.7% CAGR.

Professional Healthcare Segment to Record 15.8% CAGR

In the global Professional Healthcare segment, USA, Canada, Japan, China and Europe will drive the 14.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of 13.8 Million Units in the year 2020 will reach a projected size of 36.4 Million Units by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach 68 Million Units by the year 2027, while Latin America will expand at a 17.5% CAGR through the analysis period.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Key Topics Covered: 




  • Wireless Health and Fitness Devices: Enabling Intelligent, Convenient, Virtual, Passive, and Continuous Healthcare Monitoring
  • Growth Drivers in a Nutshell
  • Key Challenges Summarized
  • Recent Market Activity
  • Convergence of Health and Fitness Devices with Information Technology Transform the Healthcare Industry
  • Wireless Healthcare Devices: Merger of Consumer Electronics with Professional Medical Equipment
  • Wearable Technology: Intertwined Closely with the Expanding Healthcare Delivery Model
  • Products and Apps that Integrate Data from Varied Sources: Future of Fitness and Health Tracking Devices
Read More

Global Cancer Antibodies Drug Conjugate Antibody Market To Reach USD 13 Billion By 2026

New Product Launches & Increasing Sales Of Existing Products To Drive the market Says Kuick Research

DELHI, India, Oct. 23, 2020 (GLOBE NEWSWIRE) — “Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026” Report Highlights:

  • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs

  • Marketed Cancer Antibody Drug Conjugate: 9 Drugs

  • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026

  • Majority of Drug Trials Are For Second Line Therapy Or Greater

  • USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs

  • Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs

  • Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs

Download Report:

Download “Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026” Report:–trends-clinical-trials-emicizumab-hemlibra-blincyto–blinatumomab-sales

Worldwide cancer is among the leading cause of death. The unprecedented level of cancer cases at a global level is increasing due to the increase in life expectancy. In this overall scenario, researchers across the world have made significant development in the medical sector and have come up with antibody drug market as a mature therapeutic area for millions of patients. Despite of all the efforts that were put in improving old and traditional therapies, researchers were not able to provide and make a remarkable change in the cancer therapeutics market but the arrival of antibody drug market for the cancer patients have helped in achieving unexpected clinical results.

The better understanding of pathophysiology of cancer have led to the discovery of novel targets present on the surface of cancer cells and eventually antibody development against the target. The discovery of several novel molecular targets on the cancer cells have refreshed the overall expectations of providing better standard healthcare for millions of cancer patients across the world. Since the development of the market that focuses on antibody development, several noteworthy advances have been made, which have eventually marked the therapy as one of the most significant markets ever made in the cancer therapeutics sector.

The further classification of the market in monoclonal antibody market and bispecific antibody market have led to the emergence of the whole market as a therapy that focuses on improving the drug selectivity and reducing the overall adverse effects, which however are some of the mainstream challenges found in the cancer market. The current panorama of the market with respect to the research and development is focused on bringing major advancement to the overall clinical platform development. In addition, the drivers coupled with the market are also believed to be providing all the regulatory updates required for the smooth functioning of the market with respect to abolishing all the challenges that were perceived as difficult when resolved through other available cancer therapies.

The global pharmaceutical sector is currently poised towards antibody market for the overall growth and expansion of both the markets i.e. antibody drug market and cancer therapeutics market. In the next few years in line, the market is estimated to be growing and providing several trends for the patients,

Read More

Global Sports Nutrition Market | Expansion of Distribution Channels to Boost the Market Growth

The global sports nutrition market size is poised to grow by USD 8.74 billion during 2020-2024, progressing at a CAGR of almost 8% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here:

Technavio has announced its latest market research report titled Global Sports Nutrition Market 2020-2024 (Graphic: Business Wire)

The sports nutrition market is driven by the expansion of distribution channels. The increase in demand for sports nutrition products has expanded their distribution channels. These products are one of the largest and fastest-growing categories in both retail and online channels. Products are distributed through numerous retail channels, such as large retail and mass merchandisers, supermarkets, hypermarkets, small retail stores, drug and specialty stores, fitness institutions, and various online retailers. Marketing strategies of various retail stores, which are stressing toward pushing quality ingredients and certifications including ELISA testing, gluten-free, or third-party banned substance testing certificates, are fueling the sales of sports supplements in the global market. The online distribution channels of the global sports nutrition market are expected to grow at a rapid pace, and the market will grow swiftly during the forecast period.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major sports nutrition market growth came from the non-protein sports nutrition segment in 2019, and is expected to register the highest growth during the forecast period.

  • North America was the largest sports nutrition market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. This is attributed to factors such as the growing demand for sports nutrition products, inclination toward healthy eating and RTD, the growing number of health clubs, and the rising demand for meal-replacement powders.

  • The global sports nutrition market is fragmented. Abbott Laboratories, Clif Bar & Co., Glanbia Plc, Klean Athlete, Momentous, MusclePharm Corp., NOW Health Group Inc., PepsiCo Inc., Pro Action srl, and Weider Global Nutrition. are some of the major market participants. To help clients improve their market position, this sports nutrition market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the global sports nutrition market 2020-2024 is expected to have positive growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Increasing use of innovative ingredients will be a Key Market Trend

The increasing use of innovative ingredients is identified as

Read More